Related Experiment Videos
Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis
Sun-Kyeong Lee1, Judith F Kalinowski, Sandra L Jastrzebski
1Department of Medicine, The University of Connecticut Health Center, Farmington, Connecticut 06030, USA. slee@neuron.uchc.edu
Abstract:
We examined the direct effects of IL-7 on osteoclastogenesis in murine bone marrow cultures, using cells from wild-type and IL-7- and IL-7 receptor (IL-7R)-deficient mice. IL-7 inhibited osteoclast-like cells (OCL) formation in macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappaB ligand (RANKL)-stimulated (both at 30 ng/ml) murine bone marrow cultures. Significant inhibitory effects were seen at 1 ng/ml (57%) and 10 ng/ml (86%). IL-7 also inhibited (P < 0.05) OCL formation in bone marrow cultures that were stimulated with vitamin D(3) (10(-8) M, 60%), bovine PTH (bPTH) (100 ng/ml, 54%), or RANKL alone (30 ng/ml, 50%). IL-7 (10 ng/ml) increased expression of the B lymphocyte marker B220 from 40-86% of total nonadherent cells in cultures treated with M-CSF and RANKL. Bone marrow cells from IL-7-deficient [IL-7 knockout (KO)] mice showed a significant (P < 0.05) increase in tartrate-resistant acid phosphatase(+) OCL numbers in cultures that were stimulated with vitamin D(3) (136 +/- 13.3%), bPTH (196 +/- 18.8%), or M-CSF and RANKL (160 +/- 7.2%). In contrast, in vitro osteoclast formation in bone marrow from IL-7R-deficient (IL-7R KO) mice showed a significant decrease in tartrate-resistant acid phosphatase(+) OCL numbers in cultures that were stimulated with vitamin D(3), PTH, RANKL, or M-CSF and RANKL. These results demonstrate that there are differences in the mechanisms regulating OCL formation between IL-7 KO and IL-7R KO cells. It seems that IL-7 is a direct inhibitor of OCL formation in vitro, based on results of adding IL-7 to wild-type cultures and the responses of IL-7 KO cells. It is unknown why IL-7R KO cells behave differently from IL-7 KO cells in vitro. However, it is possible that additional cytokines interact with IL-7R and that loss of these signals contributes to the responses of IL-7R KO cells. Alternatively, IL-7 may interact with multiple receptors.
Insights
Interleukin-7 (IL-7) directly inhibits osteoclast-like cell (OCL) formation in bone marrow cultures. IL-7 knockout mice showed increased OCL formation, while IL-7 receptor knockout mice showed decreased formation, suggesting complex regulatory mechanisms.
Area of Science:
- Immunology
- Cell Biology
- Bone Biology
Background:
- Osteoclastogenesis is a critical process for bone remodeling.
- Interleukin-7 (IL-7) is primarily known for its role in lymphocyte development.
- The direct impact of IL-7 on osteoclast formation is not fully understood.
Purpose of the Study:
- To investigate the direct effects of IL-7 on osteoclastogenesis in murine bone marrow cultures.
- To compare the osteoclast formation in wild-type, IL-7-deficient, and IL-7 receptor-deficient mice.
Main Methods:
- Murine bone marrow cultures were stimulated with M-CSF and RANKL, vitamin D3, or PTH.
- IL-7 was added to wild-type cultures to assess its direct inhibitory effects.
- Osteoclast formation was assessed by tartrate-resistant acid phosphatase (TRAP) staining.
- Gene expression of B lymphocyte marker B220 was analyzed.
Main Results:
- IL-7 significantly inhibited osteoclast-like cell (OCL) formation in wild-type bone marrow cultures across various stimulation conditions.
- IL-7 knockout (KO) cells showed significantly increased OCL formation compared to wild-type.
- IL-7 receptor (IL-7R) KO cells exhibited significantly decreased OCL formation, indicating a distinct role for the receptor.
- IL-7 treatment increased B220 expression in M-CSF and RANKL-stimulated cultures.
Conclusions:
- IL-7 acts as a direct inhibitor of osteoclast formation in vitro.
- Differences in OCL formation between IL-7 KO and IL-7R KO cells suggest complex signaling pathways involving IL-7R.
- Further research is needed to elucidate the precise mechanisms and potential interactions with other cytokines or receptors.